"\u00DAVOD: Lipoprotein-asociovan\u00E1 fosfolip\u00E1za A2 (Lp-PLA2) pravd\u011Bpodobn\u011B hraje d\u016Fle\u017Eitou roli ve v\u00FDvoji akutn\u00EDho koron\u00E1rn\u00EDho syndromu (ACS), zv\u00FD\u0161en\u00E9 hladiny Lp-PLA2 jsou spojeny s hor\u0161\u00ED progn\u00F3zou u pacient\u016F s ischemickou chorobou srde\u010Dn\u00ED. Zm\u011Bny hladin Lp-PLA2 v pr\u016Fb\u011Bhu ACS a jej\u00ED vztah ke standardn\u00EDm biomarker\u016F jsou v\u0161ak nejasn\u00E9. METODY A V\u00DDSLEDKY: Pades\u00E1t jedna po sob\u011B jdouc\u00EDch ACS pacient\u016F bylo za\u0159azeno do studie. V\u0161ichni byli l\u00E9\u010Deni \u010Dasnou invazivn\u00ED strategi\u00ED a podle st\u00E1vaj\u00EDc\u00EDch pokyn\u016F pro farmakoterapii; intenzivn\u00ED l\u00E9\u010Dba statiny byla zah\u00E1jena u v\u0161ech pacient\u016F na p\u0159ijet\u00ED. S\u00E9rov\u00E9 hladiny Lp-PLA2, LDL-cholesterolu (LDL), troponin l (TnL), a C-reaktivn\u00ED protein (CRP) byly posouzeny na p\u0159ijet\u00ED (D0), prvn\u00ED r\u00E1no (D1), a druh\u00E9 r\u00E1no hospitalizace (D2). Hladiny Lp-PLA2 (ng / ml) poklesla z 264,6 19,1 v D0, na 193,2 14,4 v D1 (P <0,001 vs D0) a 189,8 22,6 v D2 (P = 0,002 vs D0; P = nen\u00ED v\u00FDznamn\u00FD vs D1). Zm\u011Bny v hladin\u00E1ch Lp-PLA2 v\u00FDznamn\u011B korelovaly se zm\u011Bnami v LDL (r = 0,43, p = 0,008). Na druh\u00E9 stran\u011B, nebyl nalezen \u017E\u00E1dn\u00FD vztah mezi Lp-PLA2 a TnI nebo CRP. Z\u00C1V\u011ARY: Zpo\u010D\u00E1tku byly s\u00E9rov\u00E9 hladiny Lp-PLA2 v\u00FDznamn\u011B zv\u00FD\u0161eny u pacient\u016F s ACS, ale sni\u017Euj\u00ED se b\u011Bhem prvn\u00EDch 24 hodin po p\u0159ijet\u00ED a pot\u00E9 z\u016Fstaly stabiln\u00ED. Lp-PLA2 hladiny koreluj\u00ED s LDL, ale ne s TnI nebo CRP. Na\u0161e v\u00FDsledky uk\u00E1zaly dynamick\u00E9 zm\u011Bny v hladin\u011B Lp-PLA2 v ran\u00FDch f\u00E1z\u00EDch ACS, a proto nep\u0159\u00EDmo podporuj\u00ED hypot\u00E9zu o aktivn\u00ED \u00FAlohu Lp-PLA2 v patogenezi ACS."@cs . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "[72FE621662E1]" . "Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to stan"@en . "Vondr\u00E1kov\u00E1, Dagmar" . "Kr\u00FCger, Andreas" . "BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) probably plays an important role in the development of acute coronary syndrome (ACS); elevated levels of Lp-PLA2 are associated with a poorer prognosis in patients with ischemic heart disease. Alterations of Lp-PLA2 levels during ACS and its relationship to standard biomarkers are, however, unclear. FINDINGS: Fifty-one consecutive ACS patients were enrolled in the study. All were managed with early invasive strategy and according to the current guidelines for pharmacotherapy; intensive statin therapy was started in all patients at admission. Serum levels of Lp-PLA2, LDL-cholesterol (LDL), troponin l (Tnl), and C-reactive protein (CRP) were assessed at admission (D0), on the first morning (D1), and on the second morning of hospitalization (D2). Mean serum levels of Lp-PLA2 (ng/mL) decreased from 264.6 19.1 at D0, to 193.2 14.4 at D1 (P < 0.001 vs. D0) and 189.8 22.6 at D2 (P = 0.002 vs. D0; P = not significant vs. D1). Alterations in Lp-PLA2 levels significantly correlated with changes in LDL (r = 0.43; P = 0.008). On the other hand, no relationship between Lp-PLA2 and Tnl or CRP was found. CONCLUSIONS: Initially, serum levels of Lp-PLA2 were significantly elevated in ACS patients, but decreased within the first 24 hours after admission and subsequently remained stable. Lp-PLA2 levels correlated with LDL levels but not with Tnl or CRP levels. Our results demonstrated dynamic alterations in Lp-PLA2 levels during the early stages of ACS and, therefore, indirectly support the hypothesis of an active role for Lp-PLA2 in the pathogenesis of ACS."@en . "Pr\u016Fcha, Miroslav" . "\u00DAVOD: Lipoprotein-asociovan\u00E1 fosfolip\u00E1za A2 (Lp-PLA2) pravd\u011Bpodobn\u011B hraje d\u016Fle\u017Eitou roli ve v\u00FDvoji akutn\u00EDho koron\u00E1rn\u00EDho syndromu (ACS), zv\u00FD\u0161en\u00E9 hladiny Lp-PLA2 jsou spojeny s hor\u0161\u00ED progn\u00F3zou u pacient\u016F s ischemickou chorobou srde\u010Dn\u00ED. Zm\u011Bny hladin Lp-PLA2 v pr\u016Fb\u011Bhu ACS a jej\u00ED vztah ke standardn\u00EDm biomarker\u016F jsou v\u0161ak nejasn\u00E9. METODY A V\u00DDSLEDKY: Pades\u00E1t jedna po sob\u011B jdouc\u00EDch ACS pacient\u016F bylo za\u0159azeno do studie. V\u0161ichni byli l\u00E9\u010Deni \u010Dasnou invazivn\u00ED strategi\u00ED a podle st\u00E1vaj\u00EDc\u00EDch pokyn\u016F pro farmakoterapii; intenzivn\u00ED l\u00E9\u010Dba statiny byla zah\u00E1jena u v\u0161ech pacient\u016F na p\u0159ijet\u00ED. S\u00E9rov\u00E9 hladiny Lp-PLA2, LDL-cholesterolu (LDL), troponin l (TnL), a C-reaktivn\u00ED protein (CRP) byly posouzeny na p\u0159ijet\u00ED (D0), prvn\u00ED r\u00E1no (D1), a druh\u00E9 r\u00E1no hospitalizace (D2). Hladiny Lp-PLA2 (ng / ml) poklesla z 264,6 19,1 v D0, na 193,2 14,4 v D1 (P <0,001 vs D0) a 189,8 22,6 v D2 (P = 0,002 vs D0; P = nen\u00ED v\u00FDznamn\u00FD vs D1). Zm\u011Bny v hladin\u00E1ch Lp-PLA2 v\u00FDznamn\u011B korelovaly se zm\u011Bnami v LDL (r = 0,43, p = 0,008). Na druh\u00E9 stran\u011B, nebyl nalezen \u017E\u00E1dn\u00FD vztah mezi Lp-PLA2 a TnI nebo CRP. Z\u00C1V\u011ARY: Zpo\u010D\u00E1tku byly s\u00E9rov\u00E9 hladiny Lp-PLA2 v\u00FDznamn\u011B zv\u00FD\u0161eny u pacient\u016F s ACS, ale sni\u017Euj\u00ED se b\u011Bhem prvn\u00EDch 24 hodin po p\u0159ijet\u00ED a pot\u00E9 z\u016Fstaly stabiln\u00ED. Lp-PLA2 hladiny koreluj\u00ED s LDL, ale ne s TnI nebo CRP. Na\u0161e v\u00FDsledky uk\u00E1zaly dynamick\u00E9 zm\u011Bny v hladin\u011B Lp-PLA2 v ran\u00FDch f\u00E1z\u00EDch ACS, a proto nep\u0159\u00EDmo podporuj\u00ED hypot\u00E9zu o aktivn\u00ED \u00FAlohu Lp-PLA2 v patogenezi ACS." . "5"^^ . . "1476-511X" . "P(NT12153)" . . . . "6"^^ . . "1"^^ . . "Zm\u011Bny hladiny lipoproteinov\u00E9 fosfolip\u00E1zy A2 a jejich vztah ke standardn\u00EDm biomarker\u016Fm u akutn\u00EDho koron\u00E1rn\u00EDho syndromu"@cs . . . "182651" . "1" . . "Lipids in health and disease" . . "RIV/00023884:_____/12:#0005464!RIV14-MZ0-00023884" . "Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to stan"@en . . . "Zm\u011Bny hladiny lipoproteinov\u00E9 fosfolip\u00E1zy A2 a jejich vztah ke standardn\u00EDm biomarker\u016Fm u akutn\u00EDho koron\u00E1rn\u00EDho syndromu" . "Zm\u011Bny hladiny lipoproteinov\u00E9 fosfolip\u00E1zy A2 a jejich vztah ke standardn\u00EDm biomarker\u016Fm u akutn\u00EDho koron\u00E1rn\u00EDho syndromu"@cs . . . "RIV/00023884:_____/12:#0005464" . "O\u0161\u0165\u00E1dal, Petr" . "Zm\u011Bny hladiny lipoproteinov\u00E9 fosfolip\u00E1zy A2 a jejich vztah ke standardn\u00EDm biomarker\u016Fm u akutn\u00EDho koron\u00E1rn\u00EDho syndromu" . "Janotka, Marek" . . . . "lipoprotein-associated phospholipase A2, acute coronary syndrome, troponin,"@en . "11" . . .